- Home
- PAMT vs NTHI Comparison
PAMT vs NTHI Comparison
Compare PAMT & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAMT
- NTHI
- Stock Information
- Founded
- PAMT 1980
- NTHI 2008
- Country
- PAMT United States
- NTHI United States
- Employees
- PAMT N/A
- NTHI N/A
- Industry
- PAMT Trucking Freight/Courier Services
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- PAMT Industrials
- NTHI Health Care
- Exchange
- PAMT Nasdaq
- NTHI Nasdaq
- Market Cap
- PAMT 223.5M
- NTHI 195.5M
- IPO Year
- PAMT 1985
- NTHI N/A
- Fundamental
- Price
- PAMT $8.98
- NTHI $9.11
- Analyst Decision
- PAMT Hold
- NTHI
- Analyst Count
- PAMT 1
- NTHI 0
- Target Price
- PAMT $13.00
- NTHI N/A
- AVG Volume (30 Days)
- PAMT 10.7K
- NTHI 75.8K
- Earning Date
- PAMT 10-28-2025
- NTHI 11-14-2025
- Dividend Yield
- PAMT N/A
- NTHI N/A
- EPS Growth
- PAMT N/A
- NTHI N/A
- EPS
- PAMT N/A
- NTHI N/A
- Revenue
- PAMT $623,270,000.00
- NTHI $59,990.00
- Revenue This Year
- PAMT N/A
- NTHI N/A
- Revenue Next Year
- PAMT $12.19
- NTHI N/A
- P/E Ratio
- PAMT N/A
- NTHI N/A
- Revenue Growth
- PAMT N/A
- NTHI N/A
- 52 Week Low
- PAMT $8.91
- NTHI $3.20
- 52 Week High
- PAMT $20.65
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- PAMT 34.48
- NTHI 48.39
- Support Level
- PAMT $8.91
- NTHI $5.58
- Resistance Level
- PAMT $10.40
- NTHI $9.57
- Average True Range (ATR)
- PAMT 0.52
- NTHI 1.32
- MACD
- PAMT -0.10
- NTHI -0.23
- Stochastic Oscillator
- PAMT 4.20
- NTHI 46.45
About PAMT PAMT CORP Common Stock
PAMT Corp is a holding company that is engaged in providing truckload dry van carriers transporting general commodities throughout the continental United States, as well as the Canadian provinces of Ontario and Quebec. It has one reportable segment being motor carrier.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).